Astellas US
在场
是其中之一......
Astellas Pharma 是一家在股票代码 4503 (JP) 下上市的公司。
Astellas Pharma 在 11 个国家有直接业务。Astellas Pharma 拥有 12家子公司，其中包括 Astellas Farma Brasil、Astellas Gene Therapies 和 Astellas Netherlands。
他们在：
涉及Astellas Pharma的并购和融资。
- Astellas Pharma has announced the acquisition of Iveric Bio (公布2023七月12号).
- Astellas Pharma has announced the acquisition of Iveric Bio (公布2023五月3号).
高管
查看带有其 32 名主要高管的组织结构图
Astellas US 搜索最多的简介
- Michael Petroutsas, President
- David Fryrear, Executive Vice President and Head of Quality Assura...
- Michael Senical, Executive Director and Head of Strategy and Plann...
高管在Astellas Pharma变化
- Rika HirotaRika Hirota 将于20246月20作为 Director 加入公司 (新闻发布的2024四月26号).
- Tomoko AramakiTomoko Aramaki 将于20246月20作为 Director 加入公司 (新闻发布的2024四月26号).
创建提醒
跟踪 Astellas US 的高管变动
药店
Astellas Pharma 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
药店 行业的其他推荐联系人
消息
Astellas US 的最新新闻稿
- Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management
- Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
- FDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device
- Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
- Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
- Astellas Pharma US, Inc. | News Room - News Releases
- Japan's Ministry of Health, Labour and Welfare Approves PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma
- Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
- Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure
- Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024
- View more press releases Close
关于 Astellas US 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Michael Senical 
